233 Views
Original Research
Presentation Type: Virtual Poster
Session: Section on Advances in Therapeutics and Technology Program
Leock Y Ngo, PhD
Clinical Pharmacology & Clinical Development
Eisai Inc.
Woodcliff Lake, New Jersey
Disclosure: Eisai Inc. (Products/Services: Leock Y Ngo is an employee of Eisai Inc.) (Employee)
Ji Hyun Kim, MD, PhD
Professor
Korea University, Guro Hospital
Seoul, Inch'on-jikhalsi, Republic of Korea
Disclosure: No Financial Relationships Disclosed
Sung Chul Lim, MD, PhD
Professor
The Catholic University of Korea, St. Vincent’s Hospital
Gyeonggi-do, Inch'on-jikhalsi, Republic of Korea
Disclosure: No Financial Relationships Disclosed
Takamichi Yamamoto, MD, MS, DMSc, FAES
Vice Executive Director of the Seirei Hamamatsu General Hospital; Neurosurgeon
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, Japan
Disclosure: Daiichi-Sankyo (Products/Services: Takamichi Yamamoto has received speaker’s honoraria from Daiichi-Sankyo) (Honorarium)Eisai Inc. (Honorarium, Takamichi Yamamoto has received speaker’s honoraria, participated in advisory boards and served as Sponsor’s Responsible Medical Officer in the FREEDOM Trial (Study 342) for Eisai)UCB Pharma (Products/Services: Takamichi Yamamoto has received speaker’s honoraria from UCB Pharma) (Honorarium)
Anna Patten, PhD
Statistician
Eisai Europe Ltd.
Hatfield, England, United Kingdom
Disclosure: Eisai Europe Ltd. (Products/Services: Anna Patten is an employee of Eisai Europe Ltd.) (Employee)
Manoj Malhotra, MD
Vice President, Medical Affairs, Americas Region; Global Head Medical Affairs for Epilepsy and MS
Eisai Inc.
Woodcliff Lake, New Jersey
Disclosure: Eisai Inc. (Products/Services: Manoj Malhotra is an employee of Eisai Inc.) (Employee)